Hyperfine enrolled its first patient in a study evaluating contrast-enhanced Swoop® ultra-low-field portable MRI, marking progress toward FDA expansion of intended use and potential reimbursement via CMS's ACCESS Model launching July 2026. Point-of-care diagnostics market is forecast to reach $70.92 billion by 2032, underscoring growth potential for Hyperfine's AI-powered imaging solutions.